CTOs on the Move

Versicolor Technologies

www.versicolortechnologies.com

 
Versicolor Technologies has developed the world`s first cosmetic and therapeutic technology platform to address pigmentation and skin aging, by leveraging small molecule compounds produced naturally in the human microbiome.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Vantage Outsourcing

Vantage Outsourcing is a Effingham, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Family Care Spcalists Med Corp

Family Care Spcalists Med Corp is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Los Angeles, CA. To find more information about Family Care Spcalists Med Corp, please visit www.fcsmg.com

Claflin Canada

Claflin Canada is a Niagara Falls, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ivoclar Vivadent

Ivoclar Vivadent is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Ivoclar Vivadent is based in Buffalo, NY. You can find more information on Ivoclar Vivadent at www.ivoclarvivadent.us

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.